Navigation Links
Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients
Date:5/5/2009

ements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the efficacy and safety of KRYSTEXXA(TM) (pegloticase), our BLA filing with the FDA, the Advisory Committee, approval of the BLA, preparation for commercialization of KRYSTEXXA, and the market for KRYSTEXXA, are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, our Phase 3 clinical data and on current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the delay or failure in completing development of KRYSTEXXA and developing other product candidates; our stock price and market conditions; varying interpretations of our clinical and CMC data by the FDA; delay achieving or failure to achieve FDA approval of KRYSTEXXA; inability to manufacture commercial quantities of our products; inability to gain market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; reliance on third parties to manufacture, market and distribute many of our products; economic, political and other risks associated wit
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
2. Hector Garcia Joins Particle Sciences as Director of Quality Assurance
3. Cost-Cutting Plus Value-Add Defines Qualitys Role in a Recession
4. PhRMA, Families USA Jointly Promote Measures to Ensure Quality, Affordable Healthcare Coverage
5. Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
6. EPA Awards Lovelace Respiratory Research Institute $500,000 for Air Quality Research
7. World's First Website for Patients to Share Diagnostic-Quality Medical Images
8. Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
9. AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers
10. Managing Risk Through Quality: Ansell Healthcares Innovative Gammex(R) Glove Range on Display at Arab Health 2009
11. New Initiative Focuses on Water Quality Improvement in the Mississippi River Basin and Gulf of Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... for advanced fluid applications and designed for continuous operation up to 1500 bar. ... sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
(Date:7/29/2015)... July 29, 2015  AsureQuality and Ubiquitome have ... for applications in food and primary production sectors. ... real-time PCR device, the Freedom4. AsureQuality ... to the supermarket shelf for producers, processors and ... in animal disease control and pest management and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
Whitewater, Wis . - Sharon Ethanol , a subsidiary of <a...
... media era, there are many companies trying to aggressively use ... site revamps to well thought-out, limited-term campaigns using new media. ... some recent examples demonstrating these concepts and their perceived impact. ... Dell back at the helm, Dell is aggressively ...
... Saint Luke's Health System of Kansas City, will be a keynote ... and 10 in Madison. He recently spoke to WTN from his ... of health information technology. , , WTN : What are ... , , John Wade Wade: I think ...
Cached Biology Technology:On the case: Web lessons for connecting with customers 2On the case: Web lessons for connecting with customers 3On the case: Web lessons for connecting with customers 4On the case: Web lessons for connecting with customers 5Visions: Wade offers straight talk on e-medical records 2Visions: Wade offers straight talk on e-medical records 3Visions: Wade offers straight talk on e-medical records 4Visions: Wade offers straight talk on e-medical records 5
(Date:7/8/2015)... NEW YORK , July 8, 2015  BD ... announced BD & Guidepoint Mentor, a new ... to Guidepoint,s expert network services. BD ... technologies to improve healthcare delivery and outcomes and, with ... start-up entrepreneur will be able to directly engage with ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... , Construction of ENJOY: A Generation House, the U.S. Department ... a collaborative effort of Rutgers, The State University of New ... following a recent ground-breaking at NJIT. Once construction of ... topping-off event at NJIT with major sponsors and VIP guests. ...
... (Boston) Kenneth Walsh, PhD, FAHA, the Aram ... of the Whitaker Cardiovascular Institute at Boston University ... 2011 American Heart Association (AHA) Distinguished Scientist. The ... The AHA created a Distinguished Scientist designation ...
... University biologists identified a new way in which bacteria hijack ... new antibiotics. Zhao-Qing Luo, the associate professor of biological ... new enzyme used by the bacterium Legionella pneumophila ... cell in order to take up residence. "Legionnaires, disease ...
Cached Biology News:Team New Jersey to make precast concrete solar house reality 2BUSM professor selected as American Heart Association Distinguished Scientist 2Purdue biologists identify new strategy used by bacteria during infection 2Purdue biologists identify new strategy used by bacteria during infection 3
mCD-1 10 transcription reactions...
... x 2 , Maintenance 112 ... , Immunizations/Boost injections x5 /each ... x1 /each , Production bleed (25 ... Final Bleed ~ 100 ml blood (~50 ml serum) ...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
Biology Products: